文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

甘草对中度COVID-19肺炎患者临床症状与实验室指标影响的随机对照试验方案结构化摘要

Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-09-15

本研究为单中心、开放标签、平行组随机临床试验,在伊朗Shahid Mohammadi医院开展。计划随机纳入60例≥18岁、确诊SARS-CoV-2感染且表现为中度COVID-19肺炎需住院的患者,比较标准治疗联合甘草根提取物(D-Reglis®,760 mg每日三次,共7天)与单纯标准治疗的疗效。主要结局为7天内临床症状(发热、干咳、乏力)恢复率及副临床特征(血小板减少、淋巴细胞减少、C反应蛋白)改善。

要点

  • 纳入标准为PCR和/或抗体检测确诊、影像学提示中度肺炎需住院且住院≤48小时的患者。
  • 干预组在伊朗卫生部标准方案基础上加用甘草根提取物760 mg每日三次,疗程7天。
  • 主要结局为7天内临床症状恢复率及血小板、淋巴细胞、CRP等副临床指标改善。

核心结论

  • 该方案旨在评估甘草根提取物联合标准治疗对中度COVID-19肺炎患者临床症状和实验室指标的疗效。

研究设计与样本

  • 单中心、开放标签、平行组随机临床试验,在伊朗Shahid Mohammadi医院开展。
  • 计划随机纳入60例患者,按1:1比例分为干预组30例和对照组30例。
  • 采用电子随机数字表进行简单随机化,无盲法和安慰剂对照。

关键数值与推荐

  • 纳入标准:≥18岁(体重≥35 kg)、PCR和/或抗体检测确诊SARS-CoV-2感染、影像学提示中度COVID-19肺炎需住院、住院≤48小时、签署知情同意。
  • 排除标准:慢性心脏病、慢性高血压、严重肾衰竭、严重肝衰竭、甲状腺疾病、重度和危重型COVID-19肺炎、使用华法林/SSRIs/MAOIs/利尿剂/糖皮质激素/抗心律失常药、随机前1个月内参加过研究性抗病毒治疗、甘草过敏史、妊娠或哺乳。
  • 干预组:标准治疗联合甘草根提取物(D-Reglis®)760 mg每日三次,共7天;对照组:仅按伊朗卫生部方案标准治疗7天。
  • 主要结局:7天内临床症状(发热、干咳、乏力)恢复率及副临床特征(血小板减少、淋巴细胞减少、C反应蛋白)改善。
  • 次要结局:临床和副临床特征改善时间、住院时长及不良反应发生率,均在随机后7天内评估。

临床怎么用

  • 该方案为评估甘草作为COVID-19辅助治疗提供了随机对照试验框架,结果尚未报告。
  • 临床使用甘草提取物需注意排除甘草过敏、妊娠哺乳及特定合并用药患者。

局限性

  • 开放标签设计,无盲法和安慰剂对照,可能引入偏倚。
  • 单中心、样本量60例,统计效能和结果外推性有限。
  • 随访评估时间窗仅为随机后7天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigate the effects of Licorice (Glycyrrhiza glabra L.) root extract, an anti-inflammatory natural medicine, compared to the usual therapeutic regimen on clinical symptoms and laboratory signs in patients with confirmed COVID-19 that are moderately ill. TRIAL DESIGN: This is a single-center, open-label, randomized, clinical trial with parallel-group design. This study is being conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran. PARTICIPANTS: Both male and female patients with ≥18 years of age (≥ 35 kg of weight), admitted at the Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas for treatment, screened for the following criteria. INCLUSION CRITERIA: 1. Confirmed diagnosis of SARS-CoV-2 infection (via polymerase chain reaction [PCR] and/or antibody test). 2. Presenting as moderate COVID-19 pneumonia (via chest computed tomography (CT) and/or X-ray) requiring hospitalization. 3. Hospitalized ≤48 hours. 4. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm. EXCLUSION CRITERIA: 1. Underlying diseases, including chronic heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders. 2. Severe and critical COVID-19 pneumonia. 3. Use of warfarin, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), diuretics, corticosteroids, and antiarrhythmic drugs. 4. Treatment with Investigational and antiviral therapy in a clinical study within one month before randomization. 5. History of allergy to Licorice. 6. Pregnancy and breastfeeding. INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19 along with a Licorice-based herbal preparation (D-Reglis ®, Irandarouk Pharmaceutical Company, Iran) at a dose of 760 mg three times a day for a period of seven days. CONTROL GROUP: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol for a period of seven days. MAIN OUTCOMES: The recovery rate of clinical symptoms, including fever, dry cough, and tiredness, as well as paraclinical features, including thrombocytopenia, lymphocytopenia, and C-reactive protein, are evaluated as primary outcomes within seven days of randomization. Time to improvement of clinical and paraclinical features and length of stay in a hospital, along with the incidence of adverse reactions are also evaluated as the secondary outcomes within seven days of randomization. RANDOMIZATION: An electronic table of random numbers will be used to allocate the included participants into either control or intervention groups (in a 1:1 ratio) using the simple randomization method. BLINDING (MASKING): This is an open-label trial without blinding and placebo control. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 60 participants randomizes (30 patients allocated to the intervention group and 30 patients allocated to the control group). TRIAL STATUS: The protocol is Version 1.0, May 31, 2020. Recruitment began July 30, 2020, and is anticipated to be completed by October 30, 2020. TRIAL REGISTRATION: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is "IRCT20200506047323N2", https://www.irct.ir/trial/47990 . The registration date is 31 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Safa O, Hassani-Azad M, Farashahinejad M, et al. Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32933552. doi:10.1186/s13063-020-04706-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。